This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …

Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …

The adoptive transfer of T lymphocytes reprogrammed to target tumour cells has
demonstrated potential for treatment of various cancers,,,,,–. However, little is known about …

Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly
in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the …

Chimaeric antigen receptor (CAR) T cells can generate durable clinical responses in B-cell
haematologic malignancies. The manufacturing of these T cells typically involves their …

Age-related diseases are frequently linked to pathological immune dysfunction, including
excessive inflammation, autoreactivity and immunodeficiency. Recent analyses of human …

Despite the notable success of chimeric antigen receptor (CAR) T cell therapies in the
treatment of certain haematological malignancies, challenges remain in optimizing CAR …

Viral engineered chimeric antigen receptor (CAR) T cell therapies are potent, targeted
cancer immunotherapies, but their permanent CAR expression can lead to severe adverse …

Effective anticancer immunotherapy treatments constitute a qualitative leap in cancer
management. Nonetheless, not all patients benefit from such therapies because they fail to …

Clonal expansion of infected CD4+ T cells is a major mechanism of HIV-1 persistence and a
barrier to achieving a cure. Potential causes are homeostatic proliferation, effects of HIV-1 …